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Edited by Hans-Dieter KlenkAbstract The anti-human immunodeﬁciency virus (HIV) activ-
ity of abacavir (ABC; 1-(1S,4R)-4-[2-amino-6-(cyclopropyla-
mino)-9H-purin-9-yl]-2-cyclopentene-1-methanol) could be
markedly enhanced by administering the aryloxymethoxyalan-
inyl phosphoramidate prodrug derivative of ABC (pro-ABC-
MP) to virus-infected cell cultures. Metabolic studies with
radiolabeled ABC and pro-ABC-MP in human T-lymphocyte
and primary macrophage cell cultures revealed a signiﬁcantly
increased delivery of the activated (phosphorylated) metabolite
of ABC (ABC-MP) by pro-ABC-MP, and the concomittant
appearance of markedly higher intracellular levels of carbovir 50-
triphosphate (CBV-TP), which represents the eventual antivi-
rally active metabolite of ABC. The intracellular amounts of
ABC-MP and appearance of CBV-TP closely correlated with
the extracellular pro-ABC-MP concentrations that were admin-
istered to the cell cultures within a concentration range between
0.5 and 100 lM. The highest amounts of CBV-TP were observed
within 6–24 h after drug administration. The improved delivery
of ABC-MP and metabolic conversion to CBV-TP explain the
markedly enhanced antiviral activity of the prodrug of ABC, and
warrant further exploration of this prodrug technology on ABC
and related compounds to further enhance and optimize their
antiviral eﬃcacy.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Abacavir (ABC) (Fig. 1) represents one of the newer nu-
cleoside reverse transcriptase inhibitors (NRTIs) that are
clinically used to treat human immunodeﬁciency virus (HIV)-
infected individuals [1]. Metabolic studies on ABC revealed
that it was predominantly anabolised to its 50-monophosphate
(ABC-MP) by an adenosine phosphotransferase and subse-
quently converted to the deaminated product carbovir 50-
monophosphate (CBV-MP) by a distinct cytosolic deaminase
diﬀerent from adenylate deaminase [2,3]. CBV-MP is then
converted in two successive steps to CBV-50-triphosphate
(CBV-TP) by cellular kinases [2]. CBV-TP is the antivirally
active metabolite of ABC and inhibits the virus-encoded RT
enzyme by acting as DNA chain terminator. The maximum
velocity (Vmax) for ABC to be converted by adenosine phos-
photransferase was 55% of the corresponding value for
adenosine, but the phosphorylating capacity of this enzyme for
ABC (Vmax/Km) was only 3.6% of the value for adenosine [2].
Also, ABC proved to be a poor substrate for 50-nucleotidase
(inosine phosphotransferase), in contrast with its deamination
product CBV which was rather eﬃciently converted to CBV-
MP by 50-nucleotidase [4,5]. Thus, ABC is not very eﬃciently
converted to its monophosphate derivative by cellular en-
zymes. In fact, beside ABC, the majority of antiviral nucleo-
side analogues active against HIV have a relatively poor
aﬃnity for their activating (phosphorylating) enzyme [6]. Ex-
amples of a relatively poor conversion rate by the activating
enzyme other than ABC are stavudine (d4T) by thymidine
kinase (TK) [7,8], zalcitabine (ddC) by 20-deoxycytidine kinase
[9,10], and didanosine (ddI) by 50-nucleotidase [4,5]. Therefore,
several attempts have been undertaken to deliver activated
(phosphorylated) nucleoside analogues directly into the virus-
infected target cells [11–24]. One of these approaches has
proven very successful when applied on thymidine analogues
such as d4T. Indeed, the aryloxymethoxyalaninyl phospho-
ramidate (APA) prodrug derivative of d4T proved highly
successful in retaining anti-HIV activity in dThd kinase-deﬁ-
cient CEM cells, whereas the parent d4T compound had poor,
if any, antiviral activity in this cell line [11,12]. However, whenblished by Elsevier B.V. All rights reserved.
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(AZT), another TK-dependent nucleoside analogue, no sig-
niﬁcant antiviral activity was retained in TK-deﬁcient CEM
cells [12] as also the parent AZT compound failed to do so.
However, it is currently still unclear whether this is due to
failure of eﬃcient release of AZT-MP from the prodrug mol-
ecule or, alternatively, whether it is due to unfavorable kinetics
of AZT-MP release allowing other enzymes [i.e., 50-(de-
oxy)nucleotidases], to dephosphorylate AZT-MP before the
nucleotide kinases (dTMP kinase in the particular case) can
further anabolize the monophosphate derivative of AZT.
Thus, the aryloxymethoxyalaninyl phosphoramidate prodrug
technology is not equally eﬃcient for all types of nucleoside
analogues with regard to the eventual conversion of the parent
drugs to the triphosphate derivative [25].
It was important to reveal whether the APA approach re-
sults in an improvement of antiviral activity when applied on
ABC. In particular, a successful direct delivery of ABC-MP
into virus-infected target cells may have at least two advan-
tages. (i) Higher amounts of activated ABC-MP can be de-
livered into the intact cells circumventing the ﬁrst poor
phosphorylation step by the adenosine phosphotransferase
and leading to improved antiviral eﬃcacy of ABC. (ii) By
directly delivering ABC-MP into the cells, conversion of ABC
to its deaminated product CBV at the nucleoside level can be
avoided. Although CBV has also proven to be an eﬃcient
anti-HIV drug [26], it shows pronounced side-eﬀects (i.e., re-
nal and cardiac toxicity) that are thought to be due, at least in
part, to the parent drug itself rather than to one of its
phosphorylated derivatives [27,28]. Thus, eﬃciently delivering
the phosphorylated derivative of ABC would not only en-
hance its antiviral potency by circumventing the relatively
poor phosphorylating step by adenosine phosphotransferase,
but may also further improve its safety proﬁle in the clinic.
Therefore, the antiviral activity and metabolic conversion
pathway of ABC and its APA derivative (pro-ABC-MP) have
been studied in human T-lymphocyte and primary macro-
phage cell cultures.2. Materials and methods
2.1. Cells
Human lymphocyte CEM cells were obtained from the American
Tissue Culture Type Collection (ATCC) (Rockville, MD) and humanlymphocyte MT-4 cells were obtained from Prof. N. Yamamoto (at
that time at Tokyo University, Japan).
Monocyte/macrophages (M/M) were obtained from the blood of
healthy seronegative donors. Peripheral blood mononuclear cells
(PBMC) were separated by Ficoll-Hypaque gradient and seeded in
plastic 48-well plates (Costar, Cambridge, MA) at 1.8 106 cells/ml
in RPMI 1640 (Gibco Labs, Gaithersburg, MD) with the addition
of 50 units/ml penicillin, 50 lg/ml streptomycin, 2 mM L-gluta-
mine, and 20% heat-inactivated, mycoplasma-free and endotoxin-
free fetal calf serum (Hyclone, Logan, UT). On the sixth day of
culture, non-adherent cells were removed by repeated gentle
washing with warm medium. Adherent cells obtained with this
technique consist of over 95% diﬀerentiated M/M. Cells were al-
ways cultured in a humidiﬁed environment containing 5% CO2 at
37 C.
2.2. Viruses
HIV-1 (strain IIIB and Ba-L) was obtained from Dr. R.C. Gallo
and Dr. M. Popovic (at that time at the National Institutes of
Health, Bethesda, MD) and HIV-2 (strain ROD) was obtained from
Dr. L. Montagnier (at that time at the Pasteur Institute, Paris,
France).2.3. Anti-HIV activity of drugs in CEM, MT-4 and
monocyte/macrophage cell cultures
The activity of test compounds against HIV-1- and HIV-2-induced
cytopathicity was examined in CEM and MT-4 cell cultures at days 4–
5 post-infection, and the antiviral activity of the test compounds was
estimated by microscopical examination of virus-induced giant cell
formation (CEM) or virus-induced destruction of the cell cultures
(MT-4). HIV-1 and HIV-2 were added at 100 CCID50 to the cell
cultures [11,14].
M/M cell cultures were exposed to various concentrations of
abacavir or its aryloxymethoxyalaninyl phosphoramidate derivative
pro-ABC-MP for 20 min, then M/M were challenged with 300
TCID50/ml of HIV-1Ba-L. After 2 h of incubation, M/M were ex-
tensively washed with warm medium to remove the excess of virus
and then cultured in the presence of the same concentrations of
drug under the same conditions as before. M/M were washed and
fed every 7 days. Supernatants were collected at day 14 after virus
challenge, and virus production was determined by the antigen-
capture assay using a commercially available kit. For the assess-
ment of cytotoxicity, mock-infected M/M were treated with various
concentrations of the test compounds. Assessment of the cytotoxic
eﬀect was performed twice weekly by visual inspection and then by
counting cells and by trypan blue dye exclusion at day 14 after the
beginning of drug treatment.2.4. Metabolism of [3H]abacavir and its aryloxymethoxyalaninyl
phosphoramidate derivative pro-[3H]ABC-MP
The metabolism of radiolabeled [3H]abacavir ([3H]ABC) and its
radiolabeled pro-tide aryloxymethoxyalaninyl abacavir monophos-
phate (pro-[3H]ABC-MP) was studied in human T4 lymphocyte
40 J. Balzarini et al. / FEBS Letters 573 (2004) 38–44CEM and monocyte/macrophage cell cultures according to previ-
ously established procedures [11,17]. Brieﬂy, CEM cells were seeded
at 2–4 105 cells/ml in RPMI-1640 culture medium supplemented
with 10% fetal calf serum, 2 mM L-glutamine, and 0.075%
NaHCO3. In a ﬁrst set of experiments, 5-ml cell suspensions in 25
cm2 culture ﬂasks were incubated with 0.5 lM [3H]ABC or 0.5 lM
pro-[3H]ABC-MP (5 lCi/5 ml) for diﬀerent time periods (i.e., 2, 6,
24, 48 and 72 h). At the indicated time points, the drug-treated cell
cultures were centrifuged, washed twice with cold RPMI-1640
medium, and precipitated with cold methanol:water (60:40). In a
second set of experiments, 5-ml cell suspensions were incubated
with a variety of concentrations of [3H]ABC (0.5, 1.5, 10, 100 lM)
or pro-[3H]ABC-MP (0.1, 1.1, 10, 100 lM) (5 lCi/5 ml). At 24 h,
drug-treated cells were centrifuged, washed and precipitated as
described above. After centrifugation, the supernatants of the
samples were subjected to HPLC analysis and separated on a
Partisphere SAX column (Whatman, Clifton, NJ). A linear gradient
of 0.005 M (NH4)H2PO4 (pH 5.0) (buﬀer A) to 0.30 M
(NH4)H2PO4 (pH 5.0) (buﬀer B) was used. The retention times of
the following metabolites were as follows: ABC, carbovir (CBV)
and pro-ABC-MP: 2–3 min; ABC-MP (abacavir-50-monophos-
phate): 7–8 min; CBV-MP (carbovir-50-monophosphate) and
alaninyl ABC-MP (Ala-ABC-MP): 11–13 min; CBV-DP (carbovir-
50-diphosphate): 19–21 min; CBV-TP (carbovir-50-triphosphate):
35–38 min.
Primary M/M were obtained from normal seronegative blood
donors. Peripheral blood mononuclear cells separated on a Ficoll-
Hypaque gradient were seeded in 5-ml plastic well plates at 
1.8 106 cells/ml in RPMI-1640 medium supplemented with 50 U/
ml penicillin, 50 lg/ml streptomycin, 2 mM L-glutamine, and 20%
heat-inactivated mycoplasma/endotoxin-free fetal calf serum (Hy-
clone, Logan, UT). After 5 days, non-adherent cells were removed
by repeated gentle washings with warm medium. Such culturesTable 1
Inhibitory activity of test compounds against HIV in cell culture
Compound EC50
a (lM)
CEM MT-4
HIV-1 HIV-2 HIV-1 HIV-2
ABC 2.3 1.0 4.2 1.7 5.9 0.03 7.3 1
Pro-ABC-MP 0.05 0.01 0.07 0.02 0.20 0.06 0.26
CBV 2.0 0.0 2.3 2.4 – –
Pro-CBV-MP 1.3 0.66 0.85 0.21 – –
a 50% Eﬀective concentration, or compound concentration required to inhibi
cell cultures.
b 50% Cytostatic concentration, or compound concentration required to inh
Table 2
Metabolism of [3H]ABC and pro-[3H]ABC-MP in CEM cell cultures in fun
Time (hours) 0.5 lM [3H]ABC (pmol/109CEM cells)
ABC+CBV fr. 2–3 ABC-MP fr. 7–8 CB
2 239 112 0.99 1.4 2.2
6 137 30 ND 2.5
24 62 11 0.73 1.0 4.5
48 100 33 1.7 0.21 3.1
72 74 24 1.2 0.01 3.9
0.5 lM pro-[3H]ABC-MP (pmol/109 CEM cells)
Pro-ABC-MP+ABC+CBV
fr. 2–3
ABC-MP fr. 6–7 CB
fr.
2 136 1.41 4.7 0.8 92
6 111 37.4 3.8 0.53 94
24 77 68 3.4 1.0 54
48 24 13 1.4 0.57 26
72 13 1.6 0.64 0.46 8.
ND: not detectable. Data are means (S.D.) of two independent experimenconsist of P 95% mature macrophages. [3H]ABC (0.5 lM) and
pro-[3H]ABC-MP (0.5 lM) were then added to the M/M cultures
for 6 or 24 h. After this incubation time period, the M/M were
detached, counted in a haematocytometer chamber, and processed
for radiolabeled metabolite determination as described above. The
total number of M/M used in the individual experiments varied
from 1.53 106 to 2.19 106 cells.3. Results
3.1. Antiviral activity of ABC and pro-ABC-MP in
HIV-infected cell cultures
The anti-HIV-1 and -HIV-2 activity of ABC and its
aryloxymethoxyalaninyl phosphoramidate prodrug derivative
(pro-ABC-MP) were evaluated in CEM, MT-4 and M/M
cell cultures (Table 1). Carbovir (CBV) and its prodrug pro-
CBV-MP were included for comparative purpose. The an-
tiviral activity of the prodrug of abacavir against HIV-1 and
HIV-2 was substantially increased when compared with the
parent compound ABC both in CEM (50–70-fold) and MT-
4 (30-fold) cell cultures. In contrast, the antiviral activity
of carbovir (the deamination product of ABC) could not
signiﬁcantly be boosted when its prodrug derivative was
administered to the HIV-infected cell cultures. The antiviral
activity of pro-ABC-MP was not only improved, but its
antiviral selectivity (ratio CC50/EC50) in the CEM cell cul-
tures had also increased by 6- to 8-fold when comparedCC50
b (lM)
M/M CEM MT-4 M/M
Ba-L
.2 0.1 0.05 97 34 192 13 150 30
0.04 0.01 0.002 13 1.7 4.6 0.04 110 10
– 157 12 – –
– 123 13 – –
t virus-induced cytopathicity in MT-4 or syncytium formation in CEM
ibit CEM or MT-4 cell proliferation by 50%.
ction of incubation time
V-MP fr. 10–12 CBV-DP fr. 20–21 CBV-TP fr. 37–38
 1.2 0.92 1.3 2.5 3.5
 3.5 1.7 0.69 5.0 1.9
 2.3 0.76 1.0 4.3 2.5
 0.57 1.9 0.43 1.1 0.45
 0.70 2.4 0.06 0.57 0.60
V-MP+Ala-ABC-MP
11–13
CBV-DP fr. 19–21 CBV-TP fr. 35–38
 1.9 6.0 1.8 7.5 3.7
 1.7 15 2.2 47 8.5
 30 25 12 30 14
 7.4 8.9 1.7 9.2 2.7
0 0.24 4.3 0.28 3.2 0.88
ts.
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tiviral activity was markedly improved, but the antiviral
selectivity was not substantially changed. As observed for
HIV-1-infected lymphocytes, the antiviral activity of Pro-
ABC-MP in M/M was also markedly greater than that of
ABC (EC50s, 0.01 and 0.1 lM, respectively) (Table 1). The
antiviral selectivity of pro-ABC-MP in M/M increased more
than 6-fold when compared with the parent ABC drug
(Table 1).
3.2. Metabolism of [3H]ABC and pro-[3H]ABC in CEM cell
cultures as a function of diﬀerent incubation times
After exposure of CEM cell cultures to 0.5 lM [3H]ABC
and 0.5 lM pro-[3H]ABC-MP, the intracellular levels of the
parent compounds and their metabolites were measured at
diﬀerent time points during drug exposure (Table 2). In the
[3H]ABC-exposed cell cultures, ABC-MP was detected as well
as the 50-mono-, 50-di- and 50-triphosphates of carbovir. TheFig. 2. Metabolic conversion of ABC and pro-ABC-MP in Chighest levels of CBV-TP, the antivirally active metabolite of
ABC, were formed within 6–24 h post-exposure of the drug
to the cell cultures (4.3–5.0 pmol/109 cells). At later time
points (i.e., 48 and 72 h), CBV-TP levels progressively de-
creased to one-tenth of their highest levels recorded after 24
h. Instead, the ABC-MP and CBV-MP levels kept fairly
constant during the whole time incubation period (0.73–1.7
pmol/109 cells for ABC-MP and 2.5–4.5 pmol/109 cells for
CBV-MP).
When the CEM lymphocyte cell cultures were incubated
with the aryloxymethoxyalaninyl phosphoramidate prodrug of
ABC, 10-fold higher levels of CBV-TP (30–70 pmol/109 cells)
were recorded within 6–24 h compared with ABC-incubated
cells. All other metabolites (i.e., ABC-MP, CBV-MP and
CBV-DP) were also more abundantly formed in the pro-ABC-
MP than in the ABC-treated cell cultures, especially during the
ﬁrst 24 h of incubation. Also the alaninyl derivative of ABC-
MP (Ala-ABC-MP) was released from pro-ABC-MP but couldEM cell cultures at diﬀerent initial drug concentrations.
42 J. Balzarini et al. / FEBS Letters 573 (2004) 38–44not be adequately separated from CBV-MP in the HPLC
chromatograms. However, this metabolite seems to markedly
accumulate within the ﬁrst 2–6 h of incubation, whereafter its
levels gradually decreased.
Minor traces of radiolabeled products were also found at
HPLC elution times between 4–5, 15–17, 26–27 and 30–32 min
(data not shown). Although the nature of these metabolites
could not be identiﬁed, they were comparable in both the
ABC- and pro-ABC-MP-treated cell cultures in terms of
quantity, and therefore, are unlikely to play a contributing
role in the markedly increased antiviral activity of the ABC
prodrug.
3.3. Metabolic conversion of diﬀerent concentrations of
[3H]ABC and pro-[3H]ABC-MP in CEM cell cultures
after 24 h of incubation
Since the highest metabolite levels of ABC and pro-ABC-
MP accumulate within 6–24 h after the start of incubation, a
variety of ABC and pro-ABC-MP concentrations, ranging
between 0.5 and 100 lM, were now exposed to CEM cell
cultures for 24 h (Fig. 2). The higher the initial extracellular
drug concentration, the higher the intracellular drug metabo-
lite levels recorded. This phenomenon was observed for all
metabolites (i.e., ABC-MP, CBV-MP, CBV-DP and CBV-TP)
formed. In fact, in contrast with the ABC-derived metabolites,
the intracellular formation of the phosphorylated ABC and
CBV metabolites derived from pro-ABC-MP increased even
more abundantly at higher extracellular prodrug concentra-
tions than expected from a linearly increased dose dependency
(Fig. 2). In the ABC-exposed cell cultures the highest drug
metabolite levels were recorded for CBV-MP and CBV-TP
irrespective of the initial extracellular drug concentrations. In
the pro-ABC-MP treated cell cultures, the highest drug levels
were recorded for CBV-MP+alaninyl-ABC-MP (Ala-ABC-
MP), followed by CBV-TP. At all extracellular drug concen-
trations tested (up to 100 lM) invariably markedly higher
CBV-TP levels appeared in the pro-ABC-MP-exposed cells
than in the ABC-exposed cells. The observation that the
amounts of metabolite formation progressively increased at
higher extracellular drug concentrations indicate that none of
the enzymes responsible for the formation of the diﬀerent
metabolites of ABC and pro-ABC-MP seemed to be saturated
with regard to their substrate conversion capacity at drug
concentrations up to 100 lM.3.4. Metabolic conversion of [3H]ABC and pro-[3H]ABC-MP
in monocyte/macrophage cell cultures
The metabolic fate of [3H]ABC and pro-[3H]ABC-MP was
studied in primary monocyte/macrophage cell cultures after
incubation of the cells with the radiolabeled drugs for 6 and 24
h. For ABC, no metabolites above the detection limit could be
detected in the cell extracts (detection limit: 0.5 pmol/109
cells). In contrast, ABC-MP, CBV-MP, CBV-DP and CBV-TP
as well as alaninyl-ABC-MP appeared to a measurable extent
in the pro-ABC-MP-treated M/M cell cultures. The CBV-TP
levels were 6.0 1.65 pmol/109 cells after 6 h and 2.5 0.66
pmol/106 cells after 24 h of drug exposure. The alaninyl-ABC-
MP levels were as high as 53.7 8.9 pmol/109 cells after 6 h,
but dropped to 8.8 2.3 pmol/109 cells after 24 h. Also, ABC-
MP levels were very pronounced at the 6-h-evaluation point
(2.4 0.8 pmol/109 cells) but were already markedly lowerafter 24 h (2.0 0.90 pmol/109 cells). Thus, all pro-ABC-MP
metabolite levels were highest at the 6-h-incubation period, but
markedly declined between 6 and 24 h. Also, the CBV-TP
levels formed after 24 h were at least 5- to 10-fold higher in
pro-ABC-MP-treated than in ABC-treated M/M cell cultures
where they were under the detection limit.4. Discussion
In contrast with the APA prodrug of CBV which did not
aﬀord a superior antiviral activity against HIV in cell culture
compared with the parent CBV, the APA prodrug technol-
ogy, applied to ABC, resulted in an at least 30- to 70-fold
potentiation of the anti-HIV activity of this drug in human
T-lymphocyte cell cultures and 10-fold in primary mono-
cyte/macrophage cell cultures. These ﬁndings suggest that
eﬃcient circumvention of the ﬁrst phosphorylation step of
ABC by adenosine phosphotransferase and thus direct in-
tracellular delivery of ABC-MP had most likely been very
eﬃcient to boost the antiviral activity of the ABC prodrug.
We could indeed demonstrate that the biochemical basis of
the increased antiviral eﬃciency of the ABC prodrug is due
to an increased intracellular release of ABC-MP and, conse-
quently, an increased metabolic conversion of ABC-MP to
CBV-TP, the eventual antivirally active metabolite of ABC.
This could be shown in both T-lymphocyte and macrophage
cell cultures. In fact, when the intracellular CBV-TP levels
formed at equally antiviral ABC and pro-ABC-MP concen-
trations were compared in T-lymphocyte CEM cell cultures
(i.e., 3 lM ABC versus 0.05–0.07 lM pro-ABC-MP),
comparable intracellular CBV-TP concentrations were de-
tected after 24 h [5–10 pmol/109 CEM cells (extrapolated
from levels obtained at 1.5 and 10 lM extracellular ABC
concentrations) (Fig. 2) versus 5 pmol/109 CEM cells (ex-
trapolated from levels obtained at 0.1 lM extracellular pro-
ABC-MP concentrations (Fig. 2)]. These ﬁndings also point
to CBV-TP as the antivirally active metabolite of both ABC
and pro-ABC-MP.
Interestingly, although pro-ABC-MP was markedly more
inhibitory against HIV-1 in M/M than in T-lymphocyte cell
cultures, the eventual CBV-TP levels were clearly lower in M/
M than in T-lymphocytes. This observation seems contradic-
tory at the ﬁrst glance, but one should take into account that
M/M cultures have markedly lower dNTP pool levels than T-
lymphocytes [29], and thus, CBV-TP levels can much better
compete with the lower cellular dNTP pools to act as a (DNA
chain-terminating) substrate for HIV reverse transcriptase in
M/M than in T-lymphocytes. A similar phenomenon has been
observed earlier for other nucleoside analogues such as AZT
and ddI [29]. Our metabolic studies also revealed that all cel-
lular enzymes involved in the conversion of pro-ABC-MP to
CBV-TP (i.e., carboxyesterase(s), phosphoramidase, ABC-MP
deaminase, and the nucleotide kinases such as GMP kinase
and NDP kinase) are neither rate-limiting nor saturated to
metabolically convert ABC-MP to CBV-TP when extracellular
drug concentrations as high as 100 lM were administered to
the T-lymphocyte cell cultures. This means that in vivo intra-
cellular delivery of higher ABC-MP concentrations through
the APA prodrug technology will concomittantly result in
higher eventual concentrations of the antiviral metabolite
CBV-TP. Fig. 3 depicts the overall metabolic pathway of CBV,
NN N
N
NH
H2N
OP
O
O
NH
CHH3C
C
O OCH3
N
N N
N
NH
H2N
OP
O
O
NH
CHH3C
C
O       O
N
N N
N
NH
H2N
OP
O
O
O
N
N N
N
NH
H2N
HO
Aryloxymethoxyalaninyl-ABC-MP Alaninyl-ABC-MP ABC-MP ABC
HN
N N
N
O
H2N
OPO
O
O
PO
O
O
PO
O
O
HN
N N
N
O
H2N
OPO
OH
O
PHO
O
OH
HN
N          N
N
O
H2N
OPHO
OH
O
HN
N N
N
O
H2N
HO
CBV-TP CBV-DP CBV-MP CBV
carboxy- 
esterases phosphoramidase 5’-nucleotidase?
phosphotransferase 
5’-nucleotidase 
cytosolic 
deaminase 
adenosine 
deaminase 
Fig. 3. Metabolic conversion scheme of the aryloxymethoxyalaninyl ABC-MP prodrug to its antivirally active carbovir 50-triphosphate derivative
CBV-TP.
J. Balzarini et al. / FEBS Letters 573 (2004) 38–44 43ABC and pro-ABC-MP. Bold arrows represent the predomi-
nant metabolic ﬂow when pro-ABC-MP is administered to the
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The favorable properties of the aryloxymethoxyalaninyl
ABC-MP prodrug in HIV-infected cell cultures may have
several important advantages. First, the antiviral potency of
ABC is markedly enhanced (30- to 70-fold) through the
prodrug technology. Second, the antiviral selectivity (ratio
CC50/EC50) is also increased in CEM cell cultures (5-fold) as
well as in monocyte/macrophage cell cultures (7-fold) (but
not in MT-4 cell cultures). It would be interesting to reveal
whether in vivo formation of free CBV nucleoside may become
less prominent due to direct conversion of pro-ABC-MP to
CBV-MP through alaninyl ABC-MP and ABC-MP. Since the
toxic side eﬀects observed for CBV in drug-treated patients has
been at least partly ascribed to free CBV [26,27], appearance of
CBV nucleoside in drug-exposed individuals should be kept as
minimal as possible.
In conclusion, the aryloxymethoxyalaninyl phosphorami-
date prodrug approach has been proven very successful to be
applied to abacavir to increase its anti-HIV potency and se-
lectivity in cell culture. These ﬁndings were supported and
rationalized by our metabolic studies showing a markedly
improved intracellular formation of CBV-TP, the antivirally
active metabolite of ABC.
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